Food and Drug Administration for ARM210.

.. ARMGO Pharma gets $1 million to aid ARM210 preclinical work for DMD treatment ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical function in support of an Investigational New Medication software with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as cure for Duchenne muscular dystrophy . The funding award to ARMGO Pharma comes from MDA Venture Philanthropy , part of MDA's translational research program. Related StoriesFlorida Institute finalizes funding agreement with Genetic NetworksTesting amniotic liquid could information doctors to create delivery preparing decisions for preterm birthsDisclosing genetic risk for CHD outcomes in lower low-density lipoprotein cholesterol DMD is one of nine types of muscular dystrophy, a combined group of genetic, degenerative diseases affecting voluntary muscles primarily.Besides dealing with pharmaceutical companies, our researchers are currently working with some of the world's largest personal care and attention businesses, a true number that have expanded their R&D activities right here. The Procter & Gamble Singapore Creativity Centre, for example, will provide a lot more than 500 research jobs when it’s completed early next yr. We are fully focused on placing Singapore at the forefront of analysis in pores and skin biology and related fields, to continue to enhance the proposition for businesses to locate their research activities here.’ All three institutions may also contribute towards building manpower and knowledge capabilities in skin research.